278 related articles for article (PubMed ID: 33231532)
1. How We Do It: A Multidisciplinary Approach to
Burkett BJ; Dundar A; Young JR; Packard AT; Johnson GB; Halfdanarson TR; Eiring RA; Gansen DN; Patton CM; Kendi AT
Radiology; 2021 Feb; 298(2):261-274. PubMed ID: 33231532
[TBL] [Abstract][Full Text] [Related]
2. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
4. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
5. Guidance on
Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
[No Abstract] [Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
Ramage J; Naraev BG; Halfdanarson TR
Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
[No Abstract] [Full Text] [Related]
8. Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.
Brogsitter C; Zöphel K; Folprecht G; Eisenhofer G; Kotzerke J
Nuklearmedizin; 2017 Jun; 56(3):N19-N21. PubMed ID: 28358166
[No Abstract] [Full Text] [Related]
9. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
10. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of
Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
[TBL] [Abstract][Full Text] [Related]
12. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
13. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
14. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.
Minczeles NS; Hofland J; de Herder WW; Brabander T
Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105
[TBL] [Abstract][Full Text] [Related]
15. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?
Önner H; Abdülrezzak Ü; Tutuş A
Nucl Med Commun; 2020 Oct; 41(10):1034-1039. PubMed ID: 32516240
[TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
17. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
18. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Bushnell DL; Bodeker KL
Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
[TBL] [Abstract][Full Text] [Related]
19. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
20. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
